文献速递腹部技术与安全CT

肌肉减少症与肌肉脂肪变性同接受免疫治疗的晚期肝细胞癌患者生存相关

Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
PubMed 文献 · Eur Radiol · 2022-07-21

这项回顾性分析纳入138例接受免疫治疗的晚期肝细胞癌患者,在治疗前CT L3层面用预设阈值评估骨骼肌指数和平均肌肉衰减。肌肉减少症与肌肉脂肪变性均与更差的无进展生存和总生存相关,多因素分析中肌肉脂肪变性是无进展生存和总生存的独立预测因子,肌肉减少症是总生存的独立预测因子。

要点

  • 治疗前CT L3层面可评估肌肉减少症(骨骼肌指数)和肌肉脂肪变性(平均肌肉衰减)。
  • 肌肉减少症与更差的无进展生存(p=0.048)和总生存(p=0.002)相关。
  • 肌肉脂肪变性是无进展生存(p=0.014)和总生存(p=0.007)的独立预测因子。

核心结论

  • 肌肉减少症和肌肉脂肪变性是接受免疫治疗的晚期肝细胞癌患者的独立预后因素。

研究设计与样本

  • 回顾性分析,共纳入138例接受免疫治疗的晚期肝细胞癌患者(发现队列n=111,验证队列n=27);在治疗前CT L3层面用预设阈值评估骨骼肌指数和平均肌肉衰减。

诊断标准与关键数值

  • 肌肉减少症和肌肉脂肪变性在治疗前CT L3层面用骨骼肌指数和平均肌肉衰减的预设阈值评估;肌肉减少性肥胖定义为同时存在肌肉减少症和体重指数>25 kg/m2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the association of sarcopenia, myosteatosis, and sarcopenic obesity with survival outcomes among patients who underwent immunotherapy for advanced hepatocellular carcinoma (HCC).

METHODS: In this retrospective analysis, patients who initiated immunotherapy for advanced HCC were enrolled. Sarcopenia and myosteatosis were evaluated on pretreatment CT at L3 level by skeletal muscle index and mean muscle attenuation using predefined cutoff values. Sarcopenic obesity was defined as concurrent sarcopenia and body mass index > 25 kg/m2. The log-rank test and the Cox proportional hazards model were used to compare overall survival (OS) and progression-free survival (PFS).

RESULTS: A total of 138 patients was included (discovery cohort n = 111, validation cohort n = 27). In the discovery cohort, patients with sarcopenia exhibited significantly poorer PFS (p = 0.048) and OS (p = 0.002) than patients without sarcopenia. Patients with myosteatosis exhibited significantly poorer PFS (p < 0.001) and OS (p < 0.001) than patients without myosteatosis. Patients with sarcopenic obesity compared to patients without sarcopenic obesity exhibited significantly poorer OS (p = 0.006) but not PFS (p = 0.31). In multivariate analysis adjusting for patient demographics, tumor extent, and liver function reserve, myosteatosis remained an independent predictor of poor PFS (p = 0.014) and OS (p = 0.007); sarcopenia remained an independent predictor for poor OS (p = 0.007). The prediction models for survival outcomes built by the discovery cohort showed similar performance in the validation cohort.

CONCLUSIONS: Sarcopenia and myosteatosis are independent prognostic factors in patients who received immunotherapy for advanced HCC.

KEY POINTS: • Sarcopenia and myosteatosis can be evaluated by CT at L3 level. • Sarcopenia, myosteatosis, and sarcopenic obesity were associated with poor survival outcomes in patients who underwent immunotherapy for advanced HCC. • Myosteatosis was an independent predictor of PFS and OS, and sarcopenia was independent for OS in these patients.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Chen BB, Liang PC, Shih TT, et al. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. Eur Radiol. 2022. PMID: 35864351. doi:10.1007/s00330-022-08980-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。